Why the study?
What is the role of sex and gender in the epidemiology, clinical presentation, recurrence, risk factors, and treatment of venous thromboembolism?
What is the role of sex and gender in the epidemiology, clinical presentation, recurrence, risk factors, and treatment of venous thromboembolism?
Ignoring sex and gender in venous thromboembolism research and management can negatively impact patient outcomes, highlighting the need for systematic inclusion of these variables in future studies.
Sex/gender factors may influence VTE outcomes; leaves open the impact of prescription patterns, bias, and confounders on care.
: The role of sex and gender in determining clinical presentation, diagnostic approach and outcomes of venous thromboembolism is not fully and systematically addressed, except for hormone-related events in women. A lack of knowledge is also apparent regarding drug prescription patterns, physician bias, enrolment in clinical studies and analysis of sex-related confounders in preclinical and clinical studies. As was shown for cardiovascular disease, ignoring sex and gender in medicine can have important impact on outcomes, including mortality. In this review, we seek to address some aspects of venous thromboembolism such as epidemiology and clinical presentation, recurrence, risk factors, animal studies, safety and efficacy of antithrombotic drugs, highlighting what is known and what is not regarding the role of sex and gender, and hoping to focus some interest and to promote the inclusion of these variables in all future studies on venous thromboembolism.
No takes yet. Share an insight, caveat, or question.
Faioni et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: